Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will share data via two poster presentations at the 11^th World Congress of Melanoma and 21^st European Association of Dermato-Oncology (EADO) Congress, being held April 3-5, 2025, in Athens, Greece. The posters demonstrate the ability of the DecisionDx-Melanoma test to guide more informed, risk-aligned management decisions through the precise risk-stratification of patients with melanoma.

"The findings being presented at EADO demonstrate that DecisionDx-Melanoma provides valuable biological insights that complement traditional staging and may help clinicians tailor surveillance and treatment plans based on a patient's individual predicted risk of metastasis,” said Brent Moody, M.D., dermatologist and Mohs micrographic surgeon at Heritage Medical Associates in Nashville, Tennessee. “By better identifying which patients may benefit from intensified monitoring and adjuvant therapy, the test has the potential to significantly improve melanoma outcomes through more personalized care directed to those who need it most."

Castle will present the following posters at EADO. The corresponding abstracts can be found in the digital Book of Abstracts available for download on the EADO website.